蘇 瑀

學歷

B.Sc. (Pharmacy)	National Taiwan University, Taiwan, R.O.C.
M.Sc. (Biochemistry)	National Taiwan University, Taiwan, R.O.C.
Ph.D. (Molecular Biology)	University of Wisconsin-Madison, U.S.A.

經歷

Post-doctoral fellow	Oncology Center of the Johns Hopkins University, U.S.A.
Associate professor	Institute of Pharmacology, NYMU
Associate professor & acting director	Institute of Biopharmaceutical Sciences (IBPS), NYMU
Associate professor	IBPS, NYMU
Professor	IBPS, NYMU
Professor and director	IBPS, NYMU
Professor	IBPS, NYMU

應邀演講 (最近五年):

1. BIT's 8th Annual World Protein and Peptide Conference, April 25-28, 2015; Nanjing, China — Identification of GATA6 as a stemness-stimulating factor for human colon cancer cells (Also serve as a session chair).
2. 5th World Congress on Cancer Therapy, Sept. 28-30, 2015; Atlanta, USA — Assessment of the stemness-suppressive effects of several SHP-1 activators in human colorectal cancer cells.
3. 8th World Congress of Regenerative Medicine & Stem Cell-2015, Nov. 18-20, 2015, Shanghai, China — Identification of Thiostrepton as a novel therapeutic agent that targets human colon cancer stem cells (Also serve as a session co-chair).
4. PCS Global Cell Science and Stem Cell Conference-2016, June 11-12, 2016, Barcelona, Spain —Assessing the stemness-inhibitory effects of several SHP-1 activators in human colorectal cancer cells.
5. International Conference on Oncology & Cancer Science, June 12-14, 2017, Sydney, Australia — Identification of GATA6, a downstream target of miR-203, as a key stemness regulator in human colon cancer cells.

6. International Conference on Cancer Diagnosis & Treatment, Aug. 2-3, 2018, Oslo, Norway — Two novel SHP-1 agonists, SC-43 and SC-78, are more potent than regorafenib in suppressing the *in vitro* stemness of human colorectal cancer cells; MicroRNA-203 diminishes the stemness of human colon cancer cells mainly by suppressing *GATA6* expression (Keynote Talk).
7. 12th World Congress of Regenerative Medicine & Stem Cell (RMSC 2018), Dec. 7-9, 2018, Xian, China — MicroRNA-203 diminishes the stemness of human colon cancer cells mainly by suppressing *GATA6* expression
8. PCS 4th Global Cell Science and Stem Cell Conference-2019 (CSSC-2019), June 22 - 23, 2019, Prague, Czech Republic — GATA6 enhances the stemness of human colon cancer cells by creating a metabolic symbiosis through upregulating *LRH-1* expression.
9. BIT's 4th Annual World Congress of Digestive Disease (WCDD-2019), Nov. 9-11, 2019, Kunming, China — GATA6 enhances the stemness of human colon cancer cells by creating a metabolic symbiosis through upregulating *LRH-1* expression.

著作 (最近五年):

1. Ju S.Y., Huang C.Y. F., Huang W. C. and **Su Y*.** (2015) Identification of Thiostrepton as a novel therapeutic agent that targets human colon cancer stem cells. **Cell Death Dis.** Jul 2; 6:e1801
2. Chen M.H., Weng J.J, Cheng C.T., Wu R.C., Huang S.C., Wu J.E., Liu C.Y., Chang M.H.P., Chen M.H., Chiang K.C., Yeh T.S., **Su Y.*** and Yeh C.N.***** (2016) ALDH1A3, the major aldehyde dehydrogenase isoform in human cholangio-carcinoma cells, affects prognosis and gemcitabine resistance in cholangio-carcinoma patients. **Clin. Cancer Res.** 22, 4225-4235.
3. Yeh C.N., Chang Y.C., **Su Y**., Hsu S.S., Cheng C.T., Wu R.C., Chung Y.H., Chiang K.C., Yeh T.S., Lu M.L., Liu C.Y., Chang M.H., Chen M.H., Huang C.F., Hsiao M., Chen M.H. (2017) Identification of MALT1 as both a prognostic factor and a potential therapeutic target of regorafenib in cholangiocarcinoma patients. **Oncotarget.** 8, 113444-113459.
4. Chung S.Y., Chen Y.H., Lin P.R., Chao T.C., Su J.C., Shiau C.W. and **Su Y.*** (2018) Two novel SHP-1 agonists, SC-43 and SC-78, are more potent than regorafenib in suppressing the in vitro stemness of human colorectal cancer cells. **Cell Death Discov.** Aug 13; 5:25.
5. Chung S.Y., Huang W.C., Chen Z.S., Chao T.C. and **Su Y**.* (2020) Elucidation of the mechanism underlying CD44v6-induced transformation of IEC-6 normal intestinal epithelial cells. **J Cell. Physiol.** 235:194-209.

6. Lai H.T., Tseng W.K., Huang S.W., Chao T.C., **Su Y**.* (2020) MicroRNA-203 diminishes the stemness of human colon cancer cells by suppressing GATA6 expression. **J Cell. Physiol.** 235:2866-2880.
7. Lai H.T., Chiang C.T., Tseng W.K., Chao T.C. and **Su Y.*** (2020) GATA6 enhances the stemness of human colon cancer cells by creating a metabolic symbiosis through upregulating *LRH-1* expression. **Mol. Oncol.** Feb. 9

Manuscript in preparation

1. Tsao A. Ni., **Su Y**., Chao T.C. Dinaciclib inhibits the stemness of two subtypes of human breast cancer cells by targeting FoxM1 and Hedgehog signaling pathway.
2. Chung S.Y., Chao T.C. and **Su Y.*** The stemness-high human colon cancer cells promote angiogenesis by producing higher amounts of angiogenic cytokines via activation of the EGFR/AKT/NF-κB pathway